ESR1 and breast cancer: In the CheckMate 7FL study, we investigated whether the addition of nivolumab to anthracycline and taxane neoadjuvant CT could significantly increase pCR rates in newly diagnosed early-stage, high-risk, high-grade ER+/HER2− BC.